Corrigendum to: Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments

In the article by Juan Tamargo entitled Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments (European Cardiology Review 2019;14(1):23–32. https://doi.org/10.15420/ecr.2018.34.2), the following correction should be made:

Figure 1 should indicate an increase (↑) in haemoglobin and haematocrit, not a decrease (↓). The corrected figure appears below.

Figure 1: Potential Mechanisms Involved in the Cardioprotective and Renoprotective Effects of Sodium–glucose Cotransporter 2 Inhibitors.

BHOB = 3-beta-hydroxybutyrate; FA = fatty acid; HHF = hospitalisations for HF; MACE = major adverse cardiovascular events; NHE = Na⁺-H⁺ exchanger; P/O = ATP yield per oxygen atom consumed of oxidative phosphorylation; SGLT2 = sodium-glucose cotransporter 2; TG = tubuloglomerular.

The author apologises for this error.